nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.03.2010 | Review

Fragile histidine triad protein: structure, function, and its association with tumorogenesis

verfasst von: Md. Imtaiyaz Hassan, Abdullah Naiyer, Faizan Ahmad

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The human fragile histidine triad (FHIT) gene is a putative tumor suppressor gene, which is located at chromosome region 3p14.2. It was suggested that the loss of heterozygosity (LOH), homozygous deletions, and abnormal expression of the FHIT gene were involved in several types of human malignancies.

Materials and methods

To determine the role of FHIT in various cancers, we have performed structural and functional analysis of FHIT in detail.

Results and discussion

The protein FHIT catalyzes the Mg²⁺ dependent hydrolysis of P1-5¢-O-adenosine-P3-5¢-O-adenosine triphosphate, Ap3A, to AMP, and ADP. The reaction is thought to follow a two-step mechanism. Histidine triad proteins, named for a motif related to the sequence H-¢-H-¢-H-¢-¢- (¢, a hydrophobic amino acid), belong to superfamily of nucleotide hydrolases and transferases. This enzyme acts on the R-phosphate of ribonucleotides, and contain a ~30-kDa domain that is typically a homodimer of ~15 kDa polypeptides with catalytic site.

Conclusion

Here we have gathered information is known about biological activities of FHIT, the structural and biochemical bases for their functions. Our approach may provide a comparative framework for further investigation of FHIT.

Ahmadian M, Wistuba II, Fong KM et al (1997) Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 57:3664–3668PubMed

Albitar M, Manshouri T, Gidel C et al (2001) Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia. Leuk Res 25:859–864PubMed

Askari MD, Vo-Dinh T (2004) Implication of mitochondrial involvement in apoptotic activity of fragile histidine triad gene: application of synchronous luminescence spectroscopy. Biopolymers 73:510–523PubMed

Baffa R, Veronese ML, Santoro R et al (1998) Loss of FHIT expression in gastric carcinoma. Cancer Res 58:4708–4714PubMed

Baffa R, Gomella LG, Vecchione A et al (2000) Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 156:419–424PubMed

Barnes LD, Garrison PN, Siprashvili Z et al (1996) Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′, 5″′-P1,P3-triphosphate hydrolase. Biochemistry 35:11529–11535PubMed

Bianchi F, Tagliabue E, Menard S et al (2007) Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections. Cell Cycle 6:643–646PubMed

Brenner C (2002) Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry 41:9003–9014PubMed

Brenner C, Garrison P, Gilmour J et al (1997a) Crystal structures of HINT demonstrate that histidine triad proteins are GalT-related nucleotide-binding proteins. Nat Struct Biol 4:231–238PubMed

Brenner C, Pace HC, Garrison PN et al (1997b) Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein. Protein Eng 10:1461–1463PubMed

Brenner C, Bieganowski P, Pace HC et al (1999) The histidine triad superfamily of nucleotide-binding proteins. J Cell Physiol 181:179–187PubMed

Bugert P, Wilhelm M, Kovacs G (1997) FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas. Genes Chromosomes Cancer 20:9–15PubMed

Campiglio M, Pekarsky Y, Menard S et al (1999) FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 59:3866–3869PubMed

Cao J, Li W, Xie J et al (2006) Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication. Surg Oncol 15:223–233PubMed

Carapeti M, Aguiar RC, Sill H et al (1998) Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. Br J Cancer 78:601–605PubMed

Chaudhuri AR, Khan IA, Prasad V et al (1999) The tumor suppressor protein Fhit. A novel interaction with tubulin. J Biol Chem 274:24378–24382PubMed

Connolly DC, Greenspan DL, Wu R et al (2000) Loss of fhit expression in invasive cervical carcinomas and intraepithelial lesions associated with invasive disease. Clin Cancer Res 6:3505–3510PubMed

Corbin S, Neilly ME, Espinosa R 3rd et al (2002) Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res 62:3477–3484PubMed

De Flora S, D’Agostini F, Izzotti A et al (2007) Molecular and cytogenetical alterations induced by environmental cigarette smoke in mice heterozygous for Fhit. Cancer Res 67:1001–1006PubMed

Deka J, Kuhlmann J, Muller O (1998) A domain within the tumor suppressor protein APC shows very similar biochemical properties as the microtubule-associated protein tau. Eur J Biochem 253:591–597PubMed

Dreijerink K, Braga E, Kuzmin I et al (2001) The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 98:7504–7509PubMed

Druck T, Hadaczek P, Fu TB et al (1997) Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 57:504–512PubMed

Dustin ML, Jacobson GR, Peterson SW (1984) Effects of insulin receptor down-regulation on hexose transport in human erythrocytes. J Biol Chem 259:13660–13663PubMed

Feng X, Li L, Gao Y et al (2007) Fhit protein expression in lung cancer studied by high-throughput tissue microarray. Bull Cancer 94:E8–11PubMed

Ferens B, Kawiak A, Banecki B et al (2009) Aberration of the enzymatic activity of Fhit tumor suppressor protein enhances cancer cell death upon photodynamic therapy similarly to that driven by wild-type Fhit. Cancer Lett 280:101–109PubMed

Fong LY, Fidanza V, Zanesi N et al (2000) Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 97:4742–4747PubMed

Fouts RL, Sandusky GE, Zhang S et al (2003) Down-regulation of fragile histidine triad expression in prostate carcinoma. Cancer 97:1447–1452PubMed

Gartenhaus RB (1997) Allelic loss determination in chronic lymphocytic leukemia by immunomagnetic bead sorting and microsatellite marker analysis. Oncogene 14:375–378PubMed

Gayrard N, Cacheux V, Iborra F et al (2008) Cytogenetic studies of 24 renal epithelial tumors with von Hippel-Lindau and fragile histidine triad protein expression correlation. Arch Pathol Lab Med 132:965–973PubMed

Gayther SA, Barski P, Batley SJ et al (1997) Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 15:2119–2126PubMed

Gemma A, Hagiwara K, Ke Y et al (1997) FHIT mutations in human primary gastric cancer. Cancer Res 57:1435–1437PubMed

Glover TW, Berger C, Coyle J et al (1984) DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67:136–142PubMed

Glover TW, Coyle-Morris JF, Li FP et al (1988) Translocation t(3;8)(p14.2;q24.1) in renal cell carcinoma affects expression of the common fragile site at 3p14(FRA3B) in lymphocytes. Cancer Genet Cytogenet 31:69–73PubMed

Gnarra JR, Lerman MI, Zbar B et al (1995) Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22:3–8PubMed

Golebiowski F, Szulc A, Szutowicz A et al (2004) Ubc9-induced inhibition of diadenosine triphosphate hydrolase activity of the putative tumor suppressor protein Fhit. Arch Biochem Biophys 428:160–164PubMed

Gopalakrishnan VK, Banerjee AG, Vishwanatha JK (2003) Effect of FHIT gene replacement on growth, cell cycle and apoptosis in pancreatic cancer cells. Pancreatology 3:293–302PubMed

Greenspan DL, Connolly DC, Wu R et al (1997) Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 57:4692–4698PubMed

Guerin LA, Hoffman HT, Zimmerman MB et al (2006) Decreased fragile histidine triad gene protein expression is associated with worse prognosis in oral squamous carcinoma. Arch Pathol Lab Med 130:158–164PubMed

Guidi E, Uboldi C, Ferretti L (2008) Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH). Cytogenet Genome Res 120:173–177PubMed

Guler G, Huebner K, Himmetoglu C et al (2009) Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 115:899–908PubMed

Guo XQ, Wang SJ, Zhang LW et al (2007) DNA methylation and loss of protein expression in esophageal squamous cell carcinogenesis of high-risk area. J Exp Clin Cancer Res 26:587–594PubMed

Hadaczek P, Siprashvili Z, Markiewski M et al (1998) Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res 58:2946–2951PubMed

Hallas C, Albitar M, Letofsky J et al (1999) Loss of FHIT expression in acute lymphoblastic leukemia. Clin Cancer Res 5:2409–2414PubMed

Harrison CJ (2001) Acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 14:593–607PubMed

Hayashi S, Tanimoto K, Hajiro-Nakanishi K et al (1997) Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res 57:1981–1985PubMed

Hendricks DT, Taylor R, Reed M et al (1997) FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res 57:2112–2115PubMed

Hesketh A, Ochi K (1997) A novel method for improving Streptomyces coelicolor A3(2) for production of actinorhodin by introduction of rpsL (encoding ribosomal protein S12) mutations conferring resistance to streptomycin. J Antibiot (Tokyo) 50:532–535

Hiraoka H, Minami K, Kaneko N et al (2009) Molecular cloning of the canine fragile histidine triad (FHIT) gene and Fhit protein expression in canine peripheral blood mononuclear cells. J Vet Med Sci 71:645–649PubMed

Holschneider CH, Baldwin RL, Tumber K et al (2005) The fragile histidine triad gene: a molecular link between cigarette smoking and cervical cancer. Clin Cancer Res 11:5756–5763PubMed

Hsu HS, Chen TP, Hung CH et al (2007) Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 110:2019–2026PubMed

Hu B, Wang H, Wang X et al (2005) Fhit and CHK1 have opposing effects on homologous recombination repair. Cancer Res 65:8613–8616PubMed

Huber O, Weiske J (2008) Beta-catenin takes a HIT. Cell Cycle 7:1326–1331PubMed

Huebner K, Croce CM (2003) Cancer and the FRA3B/FHIT fragile locus: it’s a HIT. Br J Cancer 88:1501–1506PubMed

Huebner K, Druck T, Siprashvili Z et al (1998a) The role of deletions at the FRA3B/FHIT locus in carcinogenesis. Recent Results Cancer Res 154:200–215PubMed

Huebner K, Garrison PN, Barnes LD et al (1998b) The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 32:7–31PubMed

Iliopoulos D, Guler G, Han SY et al (2005) Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24:1625–1633PubMed

Iwai T, Yokota S, Nakao M et al (1998) Frequent aberration of FHIT gene expression in acute leukemias. Cancer Res 58:5182–5187PubMed

Jensen LJ, Kuhn M, Stark M et al (2009) STRING 8–a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 37:D412–D416PubMed

Ji L, Fang B, Yen N et al (1999) Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59:3333–3339PubMed

Kantarjian HM, Talpaz M, O’Brien S et al (1999) Significance of FHIT expression in chronic myelogenous leukemia. Clin Cancer Res 5:4059–4064PubMed

Kastury K, Baffa R, Druck T et al (1996) Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 56:978–983PubMed

Ki KD, Lee SK, Tong SY et al (2008) Role of 5′-CpG island hypermethylation of the FHIT gene in cervical carcinoma. J Gynecol Oncol 19:117–122PubMed

Kim I, Crippen GM, Amidon GL (2004) Structure and specificity of a human valacyclovir activating enzyme: a homology model of BPHL. Mol Pharm 1:434–446PubMed

Kisselev LL, Justesen J, Wolfson AD et al (1998) Diadenosine oligophosphates (Ap(n)A), a novel class of signalling molecules? FEBS Lett 427:157–163PubMed

Kitano T, Tian W, Umetsu K et al (2006) Origin and evolution of gene for prolactin-induced protein. Gene 383:64–70PubMed

Knudson AG (2000) Chasing the cancer demon. Annu Rev Genet 34:1–19PubMed

Kohno T, Yokota J (1999) How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 20:1403–1410PubMed

Kok K, Naylor SL, Buys CH (1997) Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 71:27–92PubMed

Koliopanos A, Avgerinos C, Paraskeva C et al (2008) Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int 7:345–356PubMed

Kraggerud SM, Aman P, Holm R et al (2002) Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis. Cancer Res 62:512–517PubMed

Kuroki T, Trapasso F, Yendamuri S et al (2003) Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 63:3724–3728PubMed

Larson AA, Kern S, Curtiss S et al (1997) High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res 57:4082–4090PubMed

Lea JS, Ashfaq R, Muneer S et al (2004) Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. J Soc Gynecol Investig 11:329–337PubMed

Lee SH (2006) Differential gene expression in nickel(II)-treated normal rat kidney cells. Res Commun Mol Pathol Pharmacol 119:77–87PubMed

Lee SH, Kim CJ, Park HK et al (2001) Characterization of aberrant FHIT transcripts in gastric adenocarcinomas. Exp Mol Med 33:124–130PubMed

Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386:623–627PubMed

Lima CD, D’Amico KL, Naday I et al (1997) MAD analysis of FHIT, a putative human tumor suppressor from the HIT protein family. Structure 5:763–774PubMed

Lin PM, Liu TC, Chang JG et al (1997) Aberrant FHIT transcripts in acute myeloid leukaemia. Br J Haematol 99:612–617PubMed

Linehan DC, Goedegebuure PS, Peoples GE et al (1995) Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155:4486–4491PubMed

Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075–3079PubMed

Luan X, Shi G, Zohouri M et al (1997) The FHIT gene is alternatively spliced in normal kidney and renal cell carcinoma. Oncogene 15:79–86PubMed

Luan X, Ramesh KH, Cannizzaro LA (1998) FHIT gene transcript alterations occur frequently in myeloproliferative and myelodysplastic diseases. Cytogenet Cell Genet 81:183–188PubMed

Lucito R, Suresh S, Walter K et al (2007) Copy-number variants in patients with a strong family history of pancreatic cancer. Cancer Biol Ther 6:1592–1599PubMedCrossRef

Mao L (1998) Tumor suppressor genes: does FHIT fit? J Natl Cancer Inst 90:412–414PubMed

Matsuyama A, Shiraishi T, Trapasso F et al (2003) Fragile site orthologs FHIT/FRA3B and Fhit/Fra14A2: evolutionarily conserved but highly recombinogenic. Proc Natl Acad Sci USA 100:14988–14993PubMed

Michael D, Beer DG, Wilke CW et al (1997) Frequent deletions of FHIT and FRA3B in Barrett’s metaplasia and esophageal adenocarcinomas. Oncogene 15:1653–1659PubMed

Moore PS, Beghelli S, Zamboni G et al (2003) Genetic abnormalities in pancreatic cancer. Mol Cancer 2:7PubMed

Mori M, Mimori K, Shiraishi T et al (2000) Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 60:1177–1182PubMed

Mulvihill DJ, Wang YH (2004) Two breakpoint clusters at fragile site FRA3B form phased nucleosomes. Genome Res 14:1350–1357PubMed

Munger K, Pietenpol JA, Pittelkow MR et al (1992) Transforming growth factor beta 1 regulation of c-myc expression, pRB phosphorylation, and cell cycle progression in keratinocytes. Cell Growth Differ 3:291–298PubMed

Murphy LC, Tsuyuki D, Myal Y et al (1987) Isolation and sequencing of a cDNA clone for a prolactin-inducible protein (PIP). Regulation of PIP gene expression in the human breast cancer cell line, T-47D. J Biol Chem 262:15236–15241PubMed

Muzny DM, Scherer SE, Kaul R et al (2006) The DNA sequence, annotation and analysis of human chromosome 3. Nature 440:1194–1198PubMed

Myal Y, Robinson DB, Iwasiow B et al (1991) The prolactin-inducible protein (PIP/GCDFP-15) gene: cloning, structure and regulation. Mol Cell Endocrinol 80:165–175PubMed

Negrini M, Monaco C, Vorechovsky I et al (1996) The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56:3173–3179PubMed

Neyaz MK, Kumar RS, Hussain S et al (2008) Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. Biomarkers 13:597–606PubMed

Ohta M, Hara N (1986) Combined modality treatment of lung cancer: present and future. Nihon Kyobu Shikkan Gakkai Zasshi 24:1186–1191PubMed

Ohta M, Kano T, Nishida Y et al (1986) Embryonal carcinoma (Higuchi, Kato) of the ovary, clinical analysis and recent improvement of treatment using alpha FP as a tumor marker. Nippon Sanka Fujinka Gakkai Zasshi 38:887–895PubMed

Ohta M, Inoue H, Cotticelli MG et al (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587–597PubMed

Okumura H, Ishii H, Pichiorri F et al (2009) Fragile gene product, Fhit, in oxidative and replicative stress responses. Cancer Sci 100:1145–1150PubMed

Osawa M, Horiuchi H, Tian W et al (2004) Divergent evolution of the prolactin-inducible protein gene and related genes in the mouse genome. Gene 325:179–186PubMed

Ottey M, Han SY, Druck T et al (2004) Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br J Cancer 91:1669–1677PubMed

Ozols RF (1994) Research directions in epithelial ovarian cancer. Gynecol Oncol 55:S168–S173PubMed

Pace HC, Garrison PN, Robinson AK et al (1998) Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci USA 95:5484–5489PubMed

Pace HC, Hodawadekar SC, Draganescu A et al (2000) Crystal structure of the worm NitFhit Rosetta Stone protein reveals a Nit tetramer binding two Fhit dimers. Curr Biol 10:907–917PubMed

Panagopoulos I, Pandis N, Thelin S et al (1996) The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res 56:4871–4875PubMed

Pandis N, Bardi G, Mitelman F et al (1997) Deletion of the short arm of chromosome 3 in breast tumors. Genes Chromosomes Cancer 18:241–245PubMed

Paulovich AG, Armour CD, Hartwell LH (1998) The Saccharomyces cerevisiae RAD9, RAD17, RAD24 and MEC3 genes are required for tolerating irreparable, ultraviolet-induced DNA damage. Genetics 150:75–93PubMed

Pecherzewska R, Nawrot B (2009) FHIT—tumor suppressor protein involved in induction of apoptosis and cell cycle regulation. Postepy Biochem 55:66–75PubMed

Pekarsky Y, Campiglio M, Siprashvili Z et al (1998a) Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc Natl Acad Sci USA 95:8744–8749PubMed

Pekarsky Y, Druck T, Cotticelli MG et al (1998b) The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells. Cancer Res 58:3401–3408PubMed

Pekarsky Y, Palamarchuk A, Huebner K et al (2002) FHIT as tumor suppressor: mechanisms and therapeutic opportunities. Cancer Biol Ther 1:232–236PubMed

Pekarsky Y, Garrison PN, Palamarchuk A et al (2004) Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 101:3775–3779PubMed

Peters UR, Hasse U, Oppliger E et al (1999) Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia. Oncogene 18:79–85PubMed

Pichiorri F, Trapasso F, Palumbo T et al (2006) Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35. Clin Cancer Res 12:3494–3501PubMed

Pichiorri F, Okumura H, Nakamura T et al (2009) Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions. J Biol Chem 284:1040–1049PubMed

Poland KS, Azim M, Folsom M et al (2007) A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. Genes Chromosomes Cancer 46:805–812PubMed

Ramp U, Caliskan E, Ebert T et al (2002) FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival. J Pathol 196:430–436PubMed

Rassool FV, Le Beau MM, Shen ML et al (1996) Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2. Genomics 35:109–117PubMed

Roz L, Andriani F, Ferreira CG et al (2004) The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene 23:9102–9110PubMed

Rugge M, Cassaro M, Farinati F et al (1996) Re: Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 88:762–763PubMed

Sanchez Y, el-Naggar A, Pathak S et al (1994) A tumor suppressor locus within 3p14–p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci USA 91:3383–3387PubMed

Sard L, Accornero P, Tornielli S et al (1999) The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 96:8489–8492PubMed

Semba S, Han SY, Qin HR et al (2006) Biological functions of mammalian Nit1, the counterpart of the invertebrate NitFhit Rosetta stone protein, a possible tumor suppressor. J Biol Chem 281:28244–28253PubMed

Seraphin B (1992) The HIT protein family: a new family of proteins present in prokaryotes, yeast and mammals. DNA Seq 3:177–179PubMed

Shi Y, Zou M, Farid NR et al (2000) Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem J 352(Pt 2):443–448PubMed

Shimada Y, Sato F, Watanabe G et al (2000) Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patient’s prognosis and smoking history. Cancer 89:5–11PubMed

Shiraishi T, Druck T, Mimori K et al (2001) Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit. Proc Natl Acad Sci USA 98:5722–5727PubMed

Shridhar R, Shridhar V, Wang X et al (1996) Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res 56:4347–4350PubMed

Siprashvili Z, Sozzi G, Barnes LD et al (1997) Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 94:13771–13776PubMed

Smith KJ, Levy DB, Maupin P et al (1994) Wild-type but not mutant APC associates with the microtubule cytoskeleton. Cancer Res 54:3672–3675PubMed

Smith DI, McAvoy S, Zhu Y et al (2007) Large common fragile site genes and cancer. Semin Cancer Biol 17:31–41PubMed

Soma T, Kaganoi J, Kawabe A et al (2006) Nicotine induces the fragile histidine triad methylation in human esophageal squamous epithelial cells. Int J Cancer 119:1023–1027PubMed

Sorio C, Baron A, Orlandini S et al (1999) The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 59:1308–1314PubMed

Sozzi G, Veronese ML, Negrini M et al (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17–26PubMed

Sozzi G, Tornielli S, Tagliabue E et al (1997) Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 57:5207–5212PubMed

Sozzi G, Huebner K, Croce CM (1998) FHIT in human cancer. Adv Cancer Res 74:141–166PubMed

Stam RW, den Boer ML, Passier MM et al (2006) Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia 20:264–271PubMed

Stec-Michalska K, Antoszczyk S, Klupinska G et al (2005) Loss of FHIT expression in gastric mucosa of patients with family histories of gastric cancer and Helicobacter pylori infection. World J Gastroenterol 11:17–21PubMed

Su T, Suzui M, Wang L et al (2003) Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci USA 100:7824–7829PubMed

Sugimoto K, Yamada K, Miyagawa K et al (1997) Decreased or altered expression of the FHIT gene in human leukemias. Stem Cells 15:223–228PubMed

Sun J, Okumura H, Yearsley M et al (2009) Nit1 and Fhit tumor suppressor activities are additive. J Cell Biochem 107:1097–1106PubMed

Sutherland GR (1991) Chromosomal fragile sites. Genet Anal Tech Appl 8:161–166PubMed

Takada S, Morita K, Hayashi K et al (2005) Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. Eur J Haematol 75:505–510PubMed

Tamura G, Sakata K, Nishizuka S et al (1997) Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Genes Chromosomes Cancer 20:98–102PubMed

Tanaka H, Shimada Y, Harada H et al (1998) Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 58:3429–3434PubMed

Thiagalingam S, Lengauer C, Leach FS et al (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13:343–346PubMed

Toledo G, Sola JJ, Lozano MD et al (2004) Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod Pathol 17:440–448PubMed

Trapasso F, Krakowiak A, Cesari R et al (2003) Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc Natl Acad Sci USA 100:1592–1597PubMed

Trapasso F, Pichiorri F, Gaspari M et al (2008) Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells. J Biol Chem 283:13736–13744PubMed

Tsujiuchi T, Sasaki Y, Kubozoe T et al (2002) Alterations of the Fhit gene in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Mol Carcinog 34:19–24PubMed

Uboldi C, Guidi E, Roperto S et al (2006) Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles. BMC Genomics 7:123PubMed

van den Berg A, Buys CH (1997) Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer 19:59–76PubMed

Vecchione A, Ishii H, Shiao YH et al (2001) Fez1/lzts1 alterations in gastric carcinoma. Clin Cancer Res 7:1546–1552PubMed

Virgilio L, Shuster M, Gollin SM et al (1996) FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93:9770–9775PubMed

Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMed

Weiske J, Albring KF, Huber O (2007) The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity. Proc Natl Acad Sci USA 104:20344–20349PubMed

Wiech T, Nikolopoulos E, Weis R et al (2009) Genome-wide analysis of genetic alterations in Barrett’s adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest 89:385–397PubMed

Wilke CM, Hall BK, Hoge A et al (1996) FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 5:187–195PubMed

Wingo PA, Tong T, Bolden S (1995) Cancer statistics. CA Cancer J Clin 45:8–30PubMed

Wistuba II, Gazdar AF, Minna JD (2001) Molecular genetics of small cell lung carcinoma. Semin Oncol 28:3–13PubMed

Woenckhaus M, Merk J, Stoehr R et al (2008) Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 39:126–136PubMed

Wu Q, Shi H, Suo Z et al (2003) 5′-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas. Ultrastruct Pathol 27:417–422PubMed

Yang HW, Piao HY, Taki T et al (1999) Pattern of FHIT gene expression in normal and leukaemic cells. Int J Cancer 81:897–901PubMed

Yang Q, Yoshimura G, Suzuma T et al (2001) Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 7:3869–3873PubMed

Yang Q, Yoshimura G, Sakurai T et al (2002) The Fragile Histidine Triad gene and breast cancer. Med Sci Monit 8:RA140–RA144PubMed

Yin DT, Lu XB, Dong MM et al (2004) Correlation of FHIT expression to cell proliferation and metastasis of laryngeal squamous cell carcinoma. Ai Zheng 23:1338–1341PubMed

Yin C, Shen LJ, Xie SM et al (2005) Expressions of FHIT and cyclin D1/CDK4 in oral cancer and oral precancerous lesions. Di Yi Jun Yi Da Xue Xue Bao 25:812–814PubMed

Yoshino K, Enomoto T, Nakamura T et al (1998) Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int J Cancer 76:176–181PubMed

Zawacka-Pankau J, Podhajska AJ (2007) Expression and simple, one-step purification of fragile histidine triad (Fhit) tumor suppressor mutant forms in Escherichia coli and their interaction with protoporphyrin IX. Biotechnol Lett 29:877–883PubMed

Zhao P, Lam AK, Lu YL et al (2006) Aberrant FHIT protein expression in classical Hodgkin’s lymphoma: a potential marker. Pathology 38:399–402PubMed

Zhao P, Lu Y, Zhong M et al (2008) Inverse correlation of aberrant expression of fragile histidine triad (FHIT) protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma. Acta Oncol 47:1557–1563PubMed

Zheng S, Ma X, Zhang L et al (2004) Hypermethylation of the 5′ CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. Cancer Res 64:2000–2006PubMed

Zochbauer-Muller S, Fong KM, Maitra A et al (2001) 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61:3581–3585PubMed

Zochbauer-Muller S, Gazdar AF, Minna JD (2002) Molecular pathogenesis of lung cancer. Annu Rev Physiol 64:681–708PubMed

Titel: Fragile histidine triad protein: structure, function, and its association with tumorogenesis
verfasst von: Md. Imtaiyaz Hassan
Abdullah Naiyer
Faizan Ahmad
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0751-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Fragile histidine triad protein: structure, function, and its association with tumorogenesis

Abstract

Background

Materials and methods

Results and discussion

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Materials and methods

Results and discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549

Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1α

Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy

Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie